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Abstract
Objectives—Optimal therapy for patients with non-small cell lung carcinoma (NSCLC) 
presenting with synchronous brain-only oligometastases (SBO) is not well defined. We sought to 
analyze the effect of differing therapeutic paradigms in this subpopulation.
Materials and Methods—We retrospectively analyzed NSCLC patients with 1-4 SBO 
diagnosed between 1/2000 and 1/2011 at our institution. Patients with T0 tumors or documented 
Karnofsky Performance Status <70 were excluded. Aggressive thoracic therapy (ATT) was 
defined as resection of the primary disease or chemoradiotherapy whose total radiation dose 
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exceeded 45 Gy. Cox proportional hazards and competing risks models were used to analyze 
factors affecting survival and first recurrence in the brain.
Results—Sixty-six patients were included. Median follow-up was 31.9 months. Intrathoracic 
disease extent included 9 stage I, 10 stage II and 47 stage III patients. Thirty-eight patients 
received ATT, 28 did not. Patients receiving ATT were younger (median age 55 vs. 60.5 years, 
p=0.027) but were otherwise similar to those who did not. Receipt of ATT was associated with 
prolonged median overall survival (OS) (26.4 vs. 10.5 months; p<0.001) with actuarial 2-year 
rates of 54% vs. 26%. ATT remained associated with OS after controlling for age, thoracic stage, 
performance status and initial brain therapy (HR 0.40, p=0.009). On multivariate analysis, the risk 
of first failure in the brain was associated with receipt of ATT (HR 3.62, p=0.032) and initial 
combined modality brain therapy (HR 0.34, p=0.046).
Conclusion—Aggressive management of thoracic disease in NSCLC patients with SBO is 
associated with improved survival. Careful management of brain disease remains important, 
especially for those treated aggressively.
Keywords
Non-small cell lung cancer; brain metastases; oligometastases; aggressive therapy; radiation 
therapy; whole brain radiotherapy; stereotactic radiosurgery
Introduction
Non-small cell lung cancer is the leading cause of cancer-related death across the world, in 
part because over 50% of patients have metastatic disease at diagnosis. Twenty percent of 
NSCLC patients will ultimately develop brain metastases, making the brain one of the most 
common sites of distant spread [1]. The prognosis for patients with brain metastases from 
NSCLC is poor, with an estimated median survival of 7 months, and therapy is generally 
given to extend life or palliate symptoms rather than for cure [2].
Brain metastases are usually accompanied by diffuse extracranial disease and mortality is 
driven by the competing risks of both intra- and extracranial progression. Patients with 
NSCLC presenting with synchronous brain-only oligometatases (SBO) may represent a 
population where the risk of death from widespread dissemination is lower, and such 
patients may benefit from aggressive therapy directed to known areas of disease. Previous 
studies have suggested that some in this subgroup have the potential for long-term survival 
if the primary tumor is managed aggressively [3-8]. These previous series largely selected 
patients for a specific therapy directed to either the thorax or brain, however, so the 
comparative value of different therapeutic approaches is unclear. We retrospectively 
analyzed patients presenting with NSCLC and SBO at our institution to determine how 
treatment paradigms were associated with survival and relapse.
Patients and Methods
We retrospectively identified patients presenting to our institution with NSCLC and SBO 
between January 1, 2000 and January 1, 2011 following approval by the institutional review 
board. Patients with identifiable primaries, 1-4 synchronous brain metastases by CT or MRI, 
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and no other evidence of distant metastatic disease confirmed by torso CT +/− bone scan or 
PET were included. Patients with a previous diagnosis of cancer or a documented Karnofsky 
Performance Status (KPS) of <70 were excluded (N=3). All patients were seen and 
discussed in the setting of a multidisciplinary thoracic Oncology clinic. While patients may 
have been eligible to participate in appropriate NSCLC protocols, there were no existing 
protocols designed specifically for this subgroup of patients during the study period. 
Aggressive thoracic therapy (ATT) was defined as either surgical resection of the primary 
disease and/or the administration of thoracic radiation therapy (RT) with dose > 45 Gy. 
Combined CNS therapy was defined as whole brain radiotherapy (WBRT) plus surgery or 
stereotactic radiosurgery (SRS) or both.
Statistical considerations
Baseline patient characteristics were compared using the Wilcoxon rank-sum or Fisher’s 
exact test. Overall survival and time to first failure were calculated from the date of 
diagnosis. Overall survival was estimated by the Kaplan-Meier method and compared using 
the log-rank test. A multivariate Cox proportional hazards model was constructed to 
evaluate factors independently associated with survival. First failure in the central nervous 
system (CNS) was estimated with death and non-CNS failure as competing risks and 
compared using Gray’s test. Competing risks regression using the method of Fine and Gray 
was used for multivariate analysis to evaluate factors independently associated with the risk 
of first failure in the CNS [9]. All p-values are two-sided. Statistical analysis was performed 
using SAS 9.2 and the cmprsk package in R version 2.6.2.
Results
Patient characteristics
66 patients met all eligibility criteria, 38 of whom received ATT and 28 who did not. 
Median age was 57 years, and median follow-up among survivors was 31.9 months. Other 
characteristics are shown in Table 1. Patients receiving ATT were younger than those that 
did not (median 55 vs. 60.5 years, p=0.027) but there were no other significant differences 
between the groups including initial CNS therapy (Table 2).
Overall survival
On univariate analysis, receipt of ATT was associated with improved overall survival 
(p<0.001). Median survival for patients receiving ATT was 26.4 months vs. 10.5 months for 
those receiving non-ATT. Actuarial 1-, 2- and 5-year survival for those receiving ATT was 
71%, 54% and 29% respectively vs. 46%, 26% and 0% for those receiving non-ATT (Figure 
1A). When stratified by stage, the benefit of ATT remained significant for patients with 
stage III disease (p=0.004), but was borderline significant for those with stage I-II disease 
(p=0.066; Figure 1B). When stratified by the number of SBO, patients with multiple 
metastases who received ATT had significantly improved survival (p<0.001) vs. non-ATT 
while those with a solitary metastasis who received ATT had a trend towards improved 
survival (p=0.111; Figure 1C).
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There was a suggestion of an early survival benefit for patients initially treated with 
combined CNS therapy (especially compared to WBRT alone), however these differences 
did not reach statistical significance (p=0.245; Figure 1D). Multivariate analysis of overall 
survival is shown in Table 3. After adjusting for age, thoracic stage, performance status and 
initial CNS therapy, ATT remained the only factor independently associated with survival 
(HR 0.40, p=0.009).
CNS first failure
Cumulative incidence curves for first failure in the CNS are shown in figure 2. Receipt of 
ATT was associated with significantly higher rates of CNS first failure (48% vs. 18% at 2 
years, p=0.015). Receipt of initial combined CNS therapy was associated with significantly 
decreased CNS first failure (26% vs. 44% at 2 years, p=0.022). For those who received 
ATT, combined CNS therapy was borderline significant for reducing CNS first failures 
(p=0.061). For those not receiving ATT, no significant benefit for combined therapy was 
seen (p=0.148). On multivariate competing risks analysis adjusting for age, performance 
status and thoracic stage, receipt of ATT was associated with a significant increase in CNS 
first failures (HR 3.62, p=0.032) while initial combined CNS therapy was associated with a 
significant reduction (HR 0.34, p=0.046; Table 4).
Discussion
Patients with NSCLC and brain metastases generally have a poor prognosis. This population 
is not homogeneous however; the Graded Prognostic Assessment index demonstrates 
median survivals ranging from 3 months to 14.8 months depending on the presence or 
absence of several prognostic factors [2]. Two of these prognostic factors relate to the 
competing risks for mortality: NSCLC patients with extracranial metastases and those with 
higher numbers of brain metastases have worse overall survival. While these variables are 
not modifiable, differences in management strategies can affect outcome, though no clear 
consensus on appropriate treatment exists for this subgroup [10]. Brain-directed therapy is 
guided by randomized data, but the relative benefits of WBRT or focal therapies in the 
context of limited extracranial disease are not well described. The potential benefit of ATT 
in this patient population has never been evaluated in a randomized fashion.
In our study, ATT was associated with improved overall survival for all thoracic stages. 
Only patients receiving ATT survived beyond 3 years. This impact on longer-term survival 
is important to note given the potential immortal time bias associated with retrospective 
analysis of lengthy treatment courses. As there is a clear tail to the survival curve for ATT, 
the perceived benefit appears to be not just definitional but representative of durable disease 
control. Indeed, the finding of potential long-term survivors in patients with oligometastatic 
lung cancer has been shown in multiple studies [11]. Significant variability is present, 
however, both in the definition of oligometastases and in the outcomes for such patients. As 
such, clearer evidence to help define an appropriate treatment path for these patients is 
needed, though mounting evidence suggests that aggressive treatment may be warranted 
given that oligometastatic NSCLC may indeed be a curable disease state.
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Our actuarial 5-year survival estimate of 29% for patients receiving ATT compares 
favorably with other published results for patients with NSCLC and SBO. Several surgical 
series looking at combined surgery for the brain and chest disease have reported 5-year 
survival rates between 7% and 27% [3, 4, 12-16]. Patients included in these studies all had 
focal management of their brain metastases with variable use of WBRT. Other series have 
reported more variable management of the primary disease, allowing for comparisons. Hu et 
al. reported a 5-year survival of 7.6% in 84 cases, all of whom underwent focal therapy to 
their brain metastases followed by WBRT in 37% [7]. No patients in this cohort underwent 
surgery for their primary disease, however, and only 25% received any type of radiation 
therapy to the chest (median dose 45 Gy). Even so, any treatment (chemotherapy or 
radiation) to address extracranial disease was associated with an overall survival benefit. 
Despite this, the authors concluded that aggressive therapy was only likely to benefit those 
with stage I disease. This recommendation is generally in line with U.S. practice guidelines 
which do not recommend ATT for those with thoracic stage III disease and SBO [17]. This 
conclusion conflicts with the findings of our study, however, which suggest that patients of 
all thoracic stages may benefit from ATT. Indeed there are emerging prospective data that 
many patients with limited metastatic disease have the potential for long-term survival if 
treated aggressively [18].
Flannery et al. reported a 21% 5-year survival for patients presenting with NSCLC and a 
solitary synchronous brain metastasis. Similar to our study, for those who underwent ATT 
the 5-year survival rate was 35% vs. 0% for those who did not [6]. Recent European 
guidelines, however, do not recommend ATT for patients with more than a solitary brain 
metastasis [19]. By comparison, Arrieta et al. reported a remarkable median survival of 31.8 
months and 2-year survival of 61% for 30 patients with one or multiple SBO who were 
treated with WBRT and induction chemotherapy followed by chemoradiotherapy for their 
primary disease [20]. This study would support our finding that ATT confers a survival 
benefit for patients with multiple SBO.
For patients with a single brain metastasis, the addition of local brain therapy (SRS or 
surgery) to WBRT is associated with improved overall survival compared to WBRT alone 
[21, 22]. The converse, however, is not true as several randomized trials have failed to 
demonstrate improved overall survival when WBRT is added to focal therapies despite 
better intracranial disease control [23-25]. This decoupling of intracranial disease 
progression from survival may be related to robust salvage of recurrences, to extracranial 
disease progression dominating as a competing risk, or a combination of factors. Patients 
with SBO, especially after ATT, may have a reduced competing risk of extracranial disease 
progression, potentially making intracranial control more important. This is supported by 
our data showing better control of the thoracic disease shifts the pattern of first failure to the 
brain. By comparison, for patients with NSCLC and SBO, Ampil et al. reported that surgical 
resection of the brain metastases was the only factor associated with improved overall 
survival [26] and Chidel et al. found that both initial WBRT and ATT were correlated with 
better overall survival [5]. Our analyses suggest that WBRT combined with focal therapy 
may be associated with a trend for improved survival in those receiving ATT.
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Limitations of this study are related to its retrospective nature including the potential for 
selection and immortal time bias as previously noted. Though we attempted to control for 
known prognostic variables by multivariate analysis, the potential for patient selection based 
on non-identified factors remains. Of note, our study also contains a significantly higher 
proportion of female patients than is seen in other reports. This may represent the unique 
makeup of patients at our institution, but also may limit generalizability. Additionally, given 
the time period covered in our study, EGFR mutation status was not available for the bulk of 
our patients. Given these limitations, our results should be interpreted with caution and used 
only for hypothesis generation. The clear benefits seen for aggressive management in our 
cohort, however, should prompt the design of prospective studies to verify the effects of 
such therapy on survival and also identify effects of such therapy on patient quality of life.
Conclusions
Patients presenting with SBO from NSCLC may represent a population with the potential 
for long-term survival when managed aggressively. Until rigorous prospective data becomes 
available, these data and similar studies support ongoing review of current clinical practice 
guidelines for this subgroup. Future research should focus on identifying clinical and 
molecular markers which can be used to identify which patients are most likely to benefit 
from ATT.
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Summary
Optimal therapy for patients with non-small cell lung carcinoma presenting with 
synchronous brain-only oligometastases is not well defined. We retrospectively analyzed 
66 non-small cell lung cancer patients with 1-4 synchronous brain-only oligometastases 
diagnosed over an 11 year period at our institution. We compared outcomes for patients 
who received aggressive thoracic therapy (surgical resection of the primary disease or 
definitive radiotherapy) to those who received less aggressive local therapy. We also 
analyzed the effect of differing treatment paradigms for the brain disease on outcomes. 
At a median follow-up of 31.9 months, receipt of aggressive thoracic therapy was 
associated with prolonged median overall survival (26.4 vs. 10.5 months). This 
association remained significant after controlling for age, thoracic stage, performance 
status and initial brain therapy. The risk of first failure in the brain was higher in those 
patients who received aggressive thoracic therapy and lower in those who received up-
front combined whole brain radiotherapy and local therapy (surgery or stereotactic 
radiosurgery).
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Highlights
• We analyzed outcomes for 66 patients with non-small cell lung cancer and 
brain-only metastases.
• Receipt of aggressive therapy for the thoracic primary was associated with 
improved survival.
• Receipt of combined whole brain and stereotactic radiotherapy decreased first 
brain failures.
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Figure 1. 
Kaplan-Meier survival curves for non-small cell lung cancer patients comparing aggressive 
thoracic therapy (ATT) to non-aggressive thoracic therapy (non-ATT) for A) all patients, B) 
patients stratified by thoracic stage or C) patients stratified by number of brain metastases, 
and D) comparing overall survival by CNS therapy type.
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Figure 2. 
Cumulative incidence curves depicting first failure in the CNS for patients stratified by A) 
receipt of aggressive thoracic therapy (ATT) and B) receipt of combined whole brain 
radiotherapy (WBRT) and focal therapy.
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Table 1
Characteristics of 66 NSCLC patients presenting with 1-4 synchronous brain metastases as their only site of 
disease.
Characteristic N %
Age (years) (Median 57, Range 35-90)
   >60 years 25 36%
   ≤60 years 41 64%
Sex
   Male 24 36%
   Female 42 64%
Histology
   Adenocarcinoma 38 58%
   Squamous cell carcinoma 9 14%
   NSCLC NOS 19 29%
KPS*
   100 12 18%
   80-90 31 47%
   70 13 20%
Thoracic stage
   IA 3 5%
   IB 6 9%
   IIA 7 11%
   IIB 3 5%
   IIIA 34 51%
   IIIB 13 20%
Number of brain metastases
   1 33 50%
   2 22 33%
   3 10 15%
   4 1 2%
Size of largest brain metastasis (cm) (Median 1.8, Range 0.1-6.1)
   ≤ 3 cm 55 83%
   > 3 cm 10 15%
   Unknown 1 2%
Initial CNS therapy
   WBRT + SRS + Surgery 3 5%
   WBRT + SRS 11 17%
   WBRT + Surgery 21 32%
   WBRT only 7 11%
   SRS + Surgery 4 6%
   SRS only 18 27%
   None 2 3%
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Characteristic N %
Initial thoracic therapy
   Surgery + RT 5 8%
   Surgery only 14 21%
   RT > 45 Gy + chemotherapy 19 29%
   RT ≤ 45 Gy +/− chemotherapy 8 12%
   Chemotherapy alone 17 26%
   Supportive care alone 3 5%
NSCLC: Non-small cell lung cancer; NOS: not otherwise specified; KPS: Karnofsky performance status; CNS: central nervous system; WBRT: 
whole brain radiotherapy; SRS: stereotactic radiosurgery; RT: radiation therapy.
*
Totals do not add up due to missing data.
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Table 2
Patient characteristics associated with the receipt of aggressive thoracic therapy.
Characteristic ATT Non-ATT p
N 38 28
Age, median 55 years 60.5 years 0.027
Sex 1.000
  Male 14 (37%) 10 (36%)
  Female 24 (63%) 18 (64%)
KPS* 0.200
  80-100 27 (84%) 16 (67%)
  70 5 (16%) 8 (33%)
Histology 0.104
  Adenocarcinoma 25 (66%) 13 (46%)
  Squamous cell 6 (16%) 3 (11%)
  NSCLC NOS 7 (18%) 12 (43%)
Thoracic stage 0.390
  I 7 (18%) 2 (7%)
  II 6 (16%) 4 (14%)
  III 25 (66%) 12 (79%)
Number of brain metastases 1.000
  1 19 (50%) 14 (50%)
  2-4 19 (50%) 14 (50%)
Size of largest brain metastasis* 0.495
  ≤ 3 cm 30 (81%) 25 (89%)
  > 3 cm 7 (19%) 3 (11%)
Initial CNS therapy 0.480
  WBRT + SRS and/or Surgery 21 (55%) 14 (50%)
  WBRT only or Surgery +/− SRS 15 (39%) 14 (50%)
  None 2 (5%) 0 (0%)
NOS: not otherwise specified; KPS: Karnofsky performance status; NSCLC: non-small cell lung cancer; CNS: central nervous system; WBRT: 
whole brain radiotherapy; SRS: stereotactic radiosurgery; ATT: aggressive thoracic therapy
*
Totals do not add up due to missing data.
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Table 3
Multivariate Cox regression analysis of factors associated with overall survival
Covariate HR p
ATT 0.40 0.009
Combined brain therapy 0.82 0.560
Age (per year) 1.02 0.262
KPS 70 vs. 80-100 1.26 0.545
Thoracic stage I-II vs. III 0.96 0.909
ATT: aggressive thoracic therapy; KPS: Karnofsky performance status
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Table 4
Multivariate competing risks analysis of factors associated with first failure in the brain
Covariate HR p
ATT 3.62 0.032
Combined brain therapy 0.34 0.046
Age (per year) 0.72 0.500
KPS 70 vs. 80-100 0.52 0.280
Thoracic stage I-II vs. III 0.62 0.480
ATT: aggressive thoracic therapy; KPS: Karnofsky performance status
Lung Cancer. Author manuscript; available in PMC 2015 October 02.
